Advertisement
Screener

Shattuck Labs, Inc. (STTK) P/E Ratio

2.8 / 5 stars · 68/120 Roast Me

Shattuck Labs, Inc. PE Ratio

The price-to-earnings (P/E) ratio tells you how many dollars investors pay for each dollar of a company's annual profit. It is market capitalization divided by net income over the trailing four quarters, meaning the four most recent filed quarters added together, and the table shows both amounts. A higher P/E means investors are paying more for each dollar of current earnings, often because they expect profits to grow; a negative P/E means the company lost money over those four quarters. Each point uses the filed share count and the last closing price on or before that quarter-end date, never today's price.

  • Shattuck Labs, Inc. pe ratio for the quarter ending 2026-06-30 was -13.3, a change of -12.68 year-over-year.
  • Shattuck Labs, Inc. pe ratio for the quarter ending 2026-03-31 was -9.76, a change of -9.12 year-over-year.
  • Shattuck Labs, Inc. pe ratio for the quarter ending 2025-12-31 was -4.72, a change of -3.95 year-over-year.
  • Shattuck Labs, Inc. pe ratio for the quarter ending 2025-09-30 was -2.71, a change of -0.48 year-over-year.
  • Shattuck Labs, Inc. pe ratio for fiscal 2026 was -13.3.
  • Shattuck Labs, Inc. pe ratio for fiscal 2025 was -4.72, a change of -3.95 from fiscal 2024.
  • Shattuck Labs, Inc. pe ratio for fiscal 2024 was -0.77, a change of 3.09 from fiscal 2023.
  • Shattuck Labs, Inc. pe ratio for fiscal 2023 was -3.86, a change of -2.9 from fiscal 2022.
Available history
2020-12-31 to 2026-06-30
Data captured

Historical PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-13.3$699.04M-$52.57M
2026-03-31-9.76$486.75M-$49.87M
2025-12-31-4.72$230.34M-$48.81M
2025-09-30-2.71$149.04M-$54.9M
2025-06-30-0.62$38.02M-$61.51M
2025-03-31-0.64$45.5M-$70.61M
2024-12-31-0.77$57.73M-$75.41M
2024-09-30-2.24$166.61M-$74.42M
2024-06-30-2.16$184.23M-$85.28M
2024-03-31-4.99$424.82M-$85.08M
2023-12-31-3.86$336.96M-$87.3M
2023-09-30-0.68$64.58M-$95.02M
2023-06-30-1.44$132.51M-$92.12M
2023-03-31-1.27$124.83M-$98.14M
2022-12-31-0.96$97.5M-$101.95M
2022-09-30-1.67$114.45M-$68.69M
2022-06-30-2.8$172.07M-$61.46M
2022-03-31-3.13$180.53M-$57.69M
2021-12-31-8.01$360.3M-$44.97M
2021-09-30-13.28$860.89M-$64.83M
2021-06-30-20.61$1.22B-$59.25M
2021-03-31-29.19$1.22B-$41.86M
2020-12-31-59.8$2.19B-$36.6M

Annual PE Ratio

DatePE RatioMarket capitalizationNet income 12 month
2026-06-30-13.3$699.04M-$52.57M
2025-12-31-4.72$230.34M-$48.81M
2024-12-31-0.77$57.73M-$75.41M
2023-12-31-3.86$336.96M-$87.3M
2022-12-31-0.96$97.5M-$101.95M
2021-12-31-8.01$360.3M-$44.97M
2020-12-31-59.8$2.19B-$36.6M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Neurogene Inc. (NGNE)$0.625B-4.46
BlossomHill Therapeutics, Inc. (BLSM)United States$0.647B
IMPACT BIOMEDICAL INC. (IBO)United States$0.611B66.47
Aquestive Therapeutics, Inc. (AQST)United States$0.606B-6.67
CorMedix Inc. (CRMD)United States$0.605B3.25
ZEVRA THERAPEUTICS, INC. (ZVRA)United States$0.668B14.61
CytomX Therapeutics, Inc. (CTMX)United States$0.598B-10.25
Monopar Therapeutics (MNPR)United States$0.598B-34.82
Altimmune, Inc. (ALT)United States$0.593B-6.43
Climb Bio, Inc. (CLYM)United States$0.683B-13.03